Recent Sentinel Activity
This recent activity feed provides a list of the last 90 days of Sentinel activity across assessments, publications & presentations, projects, events, etc.
Loading...
Recent Activity | ||||
---|---|---|---|---|
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/risk-congenital-cardiac-malformations-following-armodafinil | Risk of Congenital Cardiac Malformations Following Armodafinil or Modafinil Use: A Propensity Score Matched Analysis | Modular Programs | 11/17/2020 | Risk of Congenital Cardiac Malformations Following Armodafinil or Modafinil Use: A Propensity Score Matched AnalysisModular Programs 11/17/2020 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2016 | Duration of Follow Up for New Molecular Entities Approved in 2016 | Analyses | 04/16/2021 | Duration of Follow Up for New Molecular Entities Approved in 2016Analyses 04/16/2021 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2014-and | Duration of Follow Up for New Molecular Entities Approved in 2014 and 2015 | Analyses | 04/16/2021 | Duration of Follow Up for New Molecular Entities Approved in 2014 and 2015Analyses 04/16/2021 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2010-2012 | Duration of Follow Up for New Molecular Entities Approved in 2010, 2012, and 2013 | Analyses | 04/16/2021 | Duration of Follow Up for New Molecular Entities Approved in 2010, 2012, and 2013Analyses 04/16/2021 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2008-and | Duration of Follow Up for New Molecular Entities Approved in 2008 and 2009 | Analyses | 04/16/2021 | Duration of Follow Up for New Molecular Entities Approved in 2008 and 2009Analyses 04/16/2021 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2005-2006 | Duration of Follow Up for New Molecular Entities Approved in 2005, 2006, and 2007 | Analyses | 04/16/2021 | Duration of Follow Up for New Molecular Entities Approved in 2005, 2006, and 2007Analyses 04/16/2021 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2011 | Duration of Follow Up for New Molecular Entities Approved in 2011 | Analyses | 04/16/2021 | Duration of Follow Up for New Molecular Entities Approved in 2011Analyses 04/16/2021 |
https://www.sentinelinitiative.org/methods-data-tools/methods/treescan-pregnancy | TreeScan in Pregnancy | Methods, Data, & Tools | 07/14/2021 | TreeScan in PregnancyMethods, Data, & Tools 07/14/2021 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2017 | Duration of Follow Up for New Molecular Entities Approved in 2017: A Descriptive Analysis | Analyses | 08/13/2021 | Duration of Follow Up for New Molecular Entities Approved in 2017: A Descriptive AnalysisAnalyses 08/13/2021 |
https://www.sentinelinitiative.org/news-events/publications-presentations/how-under-coded-pediatric-hypertension-comparison-claims-and | How Under-Coded is Pediatric Hypertension?: Comparison of Claims and Electronic Health Record (EHR) Data | Publications and Presentations | 08/23/2021 | How Under-Coded is Pediatric Hypertension?: Comparison of Claims and Electronic Health Record (EHR) DataÂPublications and Presentations 08/23/2021 |
https://www.sentinelinitiative.org/news-events/publications-presentations/early-uptake-new-molecular-entities-approved-2017-multisite | Early Uptake of New Molecular Entities Approved in 2017 in a Multisite National US Healthcare Data Network | Publications and Presentations | 08/23/2021 | Early Uptake of New Molecular Entities Approved in 2017 in a Multisite National US Healthcare Data NetworkPublications and Presentations 08/23/2021 |
https://www.sentinelinitiative.org/methods-data-tools/methods/longitudinal-trends-incident-and-prevalent-use-long-acting-beta-2 | Longitudinal Trends in Incident and Prevalent use of Long-Acting Beta-2 Agonists: An Interrupted Time Series Analysis | Methods, Data, & Tools | 08/24/2021 | Longitudinal Trends in Incident and Prevalent use of Long-Acting Beta-2 Agonists: An Interrupted Time Series AnalysisMethods, Data, & Tools 08/24/2021 |
https://www.sentinelinitiative.org/methods-data-tools/methods/evaluation-existing-approaches-ehr-based-signal-identification | Evaluation of Existing Approaches to EHR-based Signal Identification | Methods, Data, & Tools | 11/19/2021 | Evaluation of Existing Approaches to EHR-based Signal IdentificationMethods, Data, & Tools 11/19/2021 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/racial-differences-covid-19-outcomes-2020-2021 | Racial Differences in COVID-19 Outcomes (2020-2021) | Assessments | 12/08/2021 | Racial Differences in COVID-19 Outcomes (2020-2021)Assessments 12/08/2021 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/intentional-self-harm-and-hospitalized-depression-following | Intentional Self-Harm and Hospitalized Depression Following Sertraline Use: A Propensity Score Matched Analysis | Analyses | 12/15/2021 | Intentional Self-Harm and Hospitalized Depression Following Sertraline Use: A Propensity Score Matched AnalysisAnalyses 12/15/2021 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/intentional-self-harm-and-hospitalized-depression-0 | Intentional Self-Harm and Hospitalized Depression Following Sertraline Use: A Propensity Score Matched Analysis (A Follow-up to a Previous Analysis) | Analyses | 12/15/2021 | Intentional Self-Harm and Hospitalized Depression Following Sertraline Use: A Propensity Score Matched Analysis (A Follow-up to a Previous Analysis)Analyses 12/15/2021 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2017-updated | Duration of Follow Up for New Molecular Entities Approved in 2017: An Updated Descriptive Analysis | Analyses | 01/21/2022 | Duration of Follow Up for New Molecular Entities Approved in 2017: An Updated Descriptive AnalysisAnalyses 01/21/2022 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2019 | Duration of Follow Up for New Molecular Entities Approved in 2019: A Descriptive Analysis | Analyses | 01/26/2022 | Duration of Follow Up for New Molecular Entities Approved in 2019: A Descriptive AnalysisAnalyses 01/26/2022 |
https://www.sentinelinitiative.org/engage-sentinel/quarterly-newsletter | Quarterly Newsletter | Spotlight | 03/24/2022 | Quarterly NewsletterSpotlight 03/24/2022 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/epidiolex-prescription-cannabidiol-utilization-patterns | Epidiolex (prescription cannabidiol) Utilization Patterns: A Descriptive Analysis | Analyses | 03/28/2022 | Epidiolex (prescription cannabidiol) Utilization Patterns: A Descriptive AnalysisAnalyses 03/28/2022 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2018 | Duration of Follow Up for New Molecular Entities Approved in 2018: A Descriptive Analysis | Analyses | 04/20/2022 | Duration of Follow Up for New Molecular Entities Approved in 2018: A Descriptive AnalysisAnalyses 04/20/2022 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/thromboembolic-stroke-major-extracranial-bleeding-0 | Thromboembolic Stroke, Major Extracranial Bleeding, Gastrointestinal Bleeding, and Intracranial Hemorrhage following Direct Oral Anticoagulant Use: An Inverse Probability of Treatment Weighting Analysis | Analyses | 04/25/2022 | Thromboembolic Stroke, Major Extracranial Bleeding, Gastrointestinal Bleeding, and Intracranial Hemorrhage following Direct Oral Anticoagulant Use: An Inverse Probability of Treatment Weighting AnalysisAnalyses 04/25/2022 |
https://www.sentinelinitiative.org/methods-data-tools/sentinel-common-data-model/sentinel-common-data-model | Sentinel Common Data Model | Methods, Data, & Tools | 06/03/2022 | Sentinel Common Data ModelMethods, Data, & Tools 06/03/2022 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/characterizing-pregnant-women-and-without-evidence-heart | Characterizing Pregnant Women With and Without Evidence of Heart Failure and Non-Pregnant Women With Heart Failure: A Propensity Score Matched Analysis | Analyses | 06/21/2022 | Characterizing Pregnant Women With and Without Evidence of Heart Failure and Non-Pregnant Women With Heart Failure: A Propensity Score Matched AnalysisAnalyses 06/21/2022 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/seizures-following-gadolinium-based-contrast-agents-exposure | Seizures Following Gadolinium-Based Contrast Agents Exposure: A Self-Controlled Risk Interval Analysis | Analyses | 06/29/2022 | Seizures Following Gadolinium-Based Contrast Agents Exposure: A Self-Controlled Risk Interval AnalysisAnalyses 06/29/2022 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/fractures-following-leuprolide-acetate-use-multiple-factor | Fractures Following Leuprolide Acetate Use: A Multiple Factor Matched Analysis (A Follow-up to a Previous Analysis) | Analyses | 09/16/2022 | Fractures Following Leuprolide Acetate Use: A Multiple Factor Matched Analysis (A Follow-up to a Previous Analysis)Analyses 09/16/2022 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-ibrexafungerp-pregnant-patients-descriptive | Utilization of Ibrexafungerp in Pregnant Patients: A Descriptive Analysis | Analyses | 10/31/2022 | Utilization of Ibrexafungerp in Pregnant Patients: A Descriptive AnalysisAnalyses 10/31/2022 |
https://www.sentinelinitiative.org/methods-data-tools/methods/onboarding-commercial-electronic-health-record-ehr-data-partners | Onboarding of Commercial Electronic Health Record (EHR) Data Partners | Methods, Data, & Tools | 11/01/2022 | Onboarding of Commercial Electronic Health Record (EHR) Data PartnersMethods, Data, & Tools 11/01/2022 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/outcome-monitoring-following-zarxio-use-signal | Outcome Monitoring Following Zarxio Use: A Signal Identification Analysis | Analyses | 11/10/2022 | Outcome Monitoring Following Zarxio Use: A Signal Identification AnalysisAnalyses 11/10/2022 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/outcome-monitoring-following-ozempic-use-patients-type-2 | Outcome Monitoring Following Ozempic Use in Patients with Type 2 Diabetes: A Signal Identification Analysis | Analyses | 11/10/2022 | Outcome Monitoring Following Ozempic Use in Patients with Type 2 Diabetes: A Signal Identification AnalysisAnalyses 11/10/2022 |
https://www.sentinelinitiative.org/news-events/meetings-workshops-trainings/2022-14th-annual-sentinel-public-workshop | 2022 14th Annual Sentinel Public Workshop | Sentinel Initiative Events | 11/15/2022 | 2022 14th Annual Sentinel Public WorkshopSentinel Initiative Events 11/15/2022 |
https://www.sentinelinitiative.org/methods-data-tools/methods/inclusion-semi-structured-and-unstructured-electronic-health-record-ehr | Inclusion of Semi-Structured and Unstructured Electronic Health Record (EHR) Data in Confounding Adjustment and Outcome Ascertainment | Methods, Data, & Tools | 12/09/2022 | Inclusion of Semi-Structured and Unstructured Electronic Health Record (EHR) Data in Confounding Adjustment and Outcome AscertainmentMethods, Data, & Tools 12/09/2022 |
https://www.sentinelinitiative.org/news-events/meetings-workshops-trainings/2023-sentinel-innovation-and-methods-seminar-series | 2023 Sentinel Innovation and Methods Seminar Series | Sentinel Initiative Events | 01/01/2023 | 2023 Sentinel Innovation and Methods Seminar SeriesSentinel Initiative Events 01/01/2023 |
https://www.sentinelinitiative.org/news-events/publications-presentations/comparative-risk-angioedema-sacubitril-valsartan-versus | Comparative Risk of Angioedema with Sacubitril-Valsartan Versus Renin-Angiotensin-Aldosterone Inhibitors | Publications and Presentations | 01/24/2023 | Comparative Risk of Angioedema with Sacubitril-Valsartan Versus Renin-Angiotensin-Aldosterone InhibitorsPublications and Presentations 01/24/2023 |
https://www.sentinelinitiative.org/methods-data-tools/methods/development-and-evaluation-electronic-health-record-ehr-information | Development and Evaluation of Electronic Health Record (EHR) Information Extraction Pipeline and Tree-Based Scan Statistic (TBSS) Methods for EHR-Based Signal Detection (DA2) | Methods, Data, & Tools | 01/27/2023 | Development and Evaluation of Electronic Health Record (EHR) Information Extraction Pipeline and Tree-Based Scan Statistic (TBSS) Methods for EHR-Based Signal Detection (DA2)Methods, Data, & Tools 01/27/2023 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/cardiovascular-outcomes-following-percutaneous-transluminal | Cardiovascular Outcomes Following Percutaneous Transluminal Septal Myocardial Ablation (PTSMA) Procedures: A Descriptive Analysis | Analyses | 02/09/2023 | Cardiovascular Outcomes Following Percutaneous Transluminal Septal Myocardial Ablation (PTSMA) Procedures: A Descriptive AnalysisAnalyses 02/09/2023 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/cardiovascular-outcomes-following-percutaneous | Cardiovascular Outcomes Following Percutaneous Transluminal Septal Myocardial Ablation (PTSMA) Procedures: An Updated Descriptive Analysis | Analyses | 02/09/2023 | Cardiovascular Outcomes Following Percutaneous Transluminal Septal Myocardial Ablation (PTSMA) Procedures: An Updated Descriptive AnalysisAnalyses 02/09/2023 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/outcome-monitoring-following-zarxio-use-updated-signal | Outcome Monitoring Following Zarxio Use: An Updated Signal Identification Analysis | Analyses | 03/08/2023 | Outcome Monitoring Following Zarxio Use: An Updated Signal Identification AnalysisAnalyses 03/08/2023 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-select-biological-products-descriptive-analysis | Utilization of Select Biological Products: A Descriptive Analysis | Analyses | 03/20/2023 | Utilization of Select Biological Products: A Descriptive AnalysisAnalyses 03/20/2023 |
https://www.sentinelinitiative.org/news-events/meetings-workshops-trainings/healthverity-being-evaluated-fda-s-sentinel-initiative | HealthVerity Being Evaluated for FDA’s Sentinel Initiative | Sentinel Initiative Events | 03/21/2023 | HealthVerity Being Evaluated for FDA’s Sentinel InitiativeSentinel Initiative Events 03/21/2023 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-select-products-migraine-treatment-and | Utilization of Select Products for Migraine Treatment and Prevention: A Descriptive Analysis | Analyses | 03/22/2023 | Utilization of Select Products for Migraine Treatment and Prevention: A Descriptive AnalysisAnalyses 03/22/2023 |
https://www.sentinelinitiative.org/news-events/publications-presentations/active-surveillance-medical-product-use-fda-s-sentinel | Active Surveillance of Medical Product Use in the FDA’s Sentinel System: A Focus on Pediatric Populations | Publications and Presentations | 03/24/2023 | Active Surveillance of Medical Product Use in the FDA’s Sentinel System: A Focus on Pediatric PopulationsPublications and Presentations 03/24/2023 |
https://www.sentinelinitiative.org/news-events/meetings-workshops-trainings/cerner-enviza-collaborates-fda-develop-innovative-ai-tools | Cerner Enviza Collaborates with FDA to Develop Innovative AI Tools for Drug Safety and Real-World Evidence Studies | Sentinel Initiative Events | 04/06/2023 | Cerner Enviza Collaborates with FDA to Develop Innovative AI Tools for Drug Safety and Real-World Evidence StudiesSentinel Initiative Events 04/06/2023 |
https://www.sentinelinitiative.org/methods-data-tools/health-outcomes-interest/covid-19-diagnosis-algorithm-defined-racial-differences | COVID-19Â Diagnosis Algorithm Defined in "Racial Differences in COVID-19 Outcomes (2020-2021)" | Methods, Data, & Tools | 04/06/2023 | COVID-19Â Diagnosis Algorithm Defined in "Racial Differences in COVID-19 Outcomes (2020-2021)"Methods, Data, & Tools 04/06/2023 |
https://www.sentinelinitiative.org/methods-data-tools/health-outcomes-interest/critical-covid-19-algorithm-defined-racial-differences | Critical COVID-19 Algorithm Defined in "Racial Differences in COVID-19 Outcomes (2020-2021)" | Methods, Data, & Tools | 04/06/2023 | Critical COVID-19 Algorithm Defined in "Racial Differences in COVID-19 Outcomes (2020-2021)"Methods, Data, & Tools 04/06/2023 |
https://www.sentinelinitiative.org/news-events/meetings-workshops-trainings/2023-sentinel-public-training-innovation-day-april-11-12 | 2023 Sentinel Public Training & Innovation Day, April 11-12 | Sentinel Initiative Events | 04/11/2023 | 2023 Sentinel Public Training & Innovation Day, April 11-12Sentinel Initiative Events 04/11/2023 |
https://www.sentinelinitiative.org/news-events/meetings-workshops-trainings/2023-sentinel-public-training-day | 2023 Sentinel Public Training Day | Sentinel Initiative Events | 04/11/2023 | 2023 Sentinel Public Training DaySentinel Initiative Events 04/11/2023 |
https://www.sentinelinitiative.org/news-events/meetings-workshops-trainings/2023-sentinel-innovation-day | 2023 Sentinel Innovation Day | Sentinel Initiative Events | 04/12/2023 | 2023 Sentinel Innovation DaySentinel Initiative Events 04/12/2023 |
https://www.sentinelinitiative.org/studies/drugs/pediatric-patients | Pediatric Patients & Hypertension | Studies | 04/13/2023 | Pediatric Patients & HypertensionStudies 04/13/2023 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/use-gonadotropin-releasing-hormone-gnrh-agonists-patients | Use of Gonadotropin-Releasing Hormone (GnRH) Agonists in Patients with Gender Dysphoria: A Descriptive Analysis | Analyses | 04/13/2023 | Use of Gonadotropin-Releasing Hormone (GnRH) Agonists in Patients with Gender Dysphoria: A Descriptive AnalysisAnalyses 04/13/2023 |
https://www.sentinelinitiative.org/methods-data-tools/routine-querying-tools/sentinel-routine-querying-system-reporting-tool | Sentinel Routine Querying System Reporting Tool | Methods, Data, & Tools | 04/14/2023 | Sentinel Routine Querying System Reporting ToolMethods, Data, & Tools 04/14/2023 |
https://www.sentinelinitiative.org/news-events/publications-presentations/valsartan-losartan-and-irbesartan-use-usa-uk-canada-and | Valsartan, Losartan and Irbesartan Use in the USA, UK, Canada and Denmark After the Nitrosamine Recalls: A Descriptive Cohort Study | Publications and Presentations | 04/17/2023 | Valsartan, Losartan and Irbesartan Use in the USA, UK, Canada and Denmark After the Nitrosamine Recalls: A Descriptive Cohort StudyPublications and Presentations 04/17/2023 |
https://www.sentinelinitiative.org/methods-data-tools/methods/creating-sentinel-linked-electronic-health-record-ehr-claims-development | Creating a Sentinel Linked Electronic Health Record (EHR)-claims Development Network | Methods, Data, & Tools | 04/18/2023 | Creating a Sentinel Linked Electronic Health Record (EHR)-claims Development NetworkMethods, Data, & Tools 04/18/2023 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/angioedema-following-sacubitrilvalsartan-use-patients-heart | Angioedema Following Sacubitril/Valsartan Use in Patients with Heart Failure: A Propensity Score Analysis | Analyses | 04/21/2023 | Angioedema Following Sacubitril/Valsartan Use in Patients with Heart Failure: A Propensity Score AnalysisAnalyses 04/21/2023 |
https://www.sentinelinitiative.org/methods-data-tools/health-outcomes-interest/angioedema-algorithm-defined-angioedema-following | Angioedema Algorithm Defined in "Angioedema Following Sacubitril/Valsartan Use in Patients with Heart Failure: An Updated Propensity Score Analysis" | Methods, Data, & Tools | 04/21/2023 | Angioedema Algorithm Defined in "Angioedema Following Sacubitril/Valsartan Use in Patients with Heart Failure: An Updated Propensity Score Analysis"Methods, Data, & Tools 04/21/2023 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/angioedema-following-sacubitrilvalsartan-use-patients-0 | Angioedema Following Sacubitril/Valsartan Use in Patients with Heart Failure: An Updated Propensity Score Matched Analysis | Analyses | 04/21/2023 | Angioedema Following Sacubitril/Valsartan Use in Patients with Heart Failure: An Updated Propensity Score Matched AnalysisAnalyses 04/21/2023 |
https://www.sentinelinitiative.org/studies/drugs/brexafemme-ibrexafungerp | Brexafemme (Ibrexafungerp) & Use in Pregnancy | Studies | 04/24/2023 | Brexafemme (Ibrexafungerp) & Use in PregnancyStudies 04/24/2023 |
https://www.sentinelinitiative.org/studies/drugs/epidiolex-prescription-cannabidiol | Epidiolex (Prescription Cannabidiol) & Utilization | Studies | 04/27/2023 | Epidiolex (Prescription Cannabidiol) & UtilizationStudies 04/27/2023 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/insulin-coding-practices-descriptive-analysis | Insulin Coding Practices: A Descriptive Analysis | Analyses | 04/27/2023 | Insulin Coding Practices: A Descriptive AnalysisAnalyses 04/27/2023 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/brand-generic-switching-patterns-among-advair-diskus-users | Brand to Generic Switching Patterns Among Advair Diskus Users with Asthma or Chronic Obstructive Pulmonary Disease (COPD): A Descriptive Analysis | Analyses | 05/01/2023 | Brand to Generic Switching Patterns Among Advair Diskus Users with Asthma or Chronic Obstructive Pulmonary Disease (COPD): A Descriptive AnalysisAnalyses 05/01/2023 |
https://www.sentinelinitiative.org/studies/drugs/ozempic-semaglutide | Ozempic (Semaglutide) & Signal Identification | Studies | 05/04/2023 | Ozempic (Semaglutide) & Signal IdentificationStudies 05/04/2023 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-and-switching-patterns-inhaled | Utilization and Switching Patterns of Inhaled Corticosteroid/Long Acting Beta Agonist and Advair Diskus in Patients with Asthma or Chronic Obstructive Pulmonary Disease: A Descriptive Analysis | Analyses | 05/04/2023 | Utilization and Switching Patterns of Inhaled Corticosteroid/Long Acting Beta Agonist and Advair Diskus in Patients with Asthma or Chronic Obstructive Pulmonary Disease: A Descriptive AnalysisAnalyses 05/04/2023 |
https://www.sentinelinitiative.org/methods-data-tools/methods/subset-calibration-methods | Subset Calibration Methods | Methods, Data, & Tools | 05/08/2023 | Subset Calibration MethodsMethods, Data, & Tools 05/08/2023 |
https://www.sentinelinitiative.org/methods-data-tools/routine-querying-tools/sentinel-routine-querying-system | Sentinel Routine Querying System | Methods, Data, & Tools | 05/16/2023 | Sentinel Routine Querying SystemMethods, Data, & Tools 05/16/2023 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/ischemic-colitis-following-alosetron-use-descriptive | Ischemic Colitis Following Alosetron Use: A Descriptive Analysis | Analyses | 05/24/2023 | Ischemic Colitis Following Alosetron Use: A Descriptive AnalysisAnalyses 05/24/2023 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/biologics-use-adults-ulcerative-colitis-descriptive-analysis | Biologics Use in Adults with Ulcerative Colitis: A Descriptive Analysis | Analyses | 05/24/2023 | Biologics Use in Adults with Ulcerative Colitis: A Descriptive AnalysisAnalyses 05/24/2023 |
https://www.sentinelinitiative.org/studies/drugs/gonadotropin-releasing-hormone-gnrh-agonists | Gonadotropin-Releasing Hormone (GnRH) Agonists & Utilization Characterization | Studies | 05/25/2023 | Gonadotropin-Releasing Hormone (GnRH) Agonists & Utilization CharacterizationStudies 05/25/2023 |
https://www.sentinelinitiative.org/news-events/publications-presentations/assessment-sentinel-system-focus-active-risk-identification | An Assessment of the Sentinel System: Focus on the Active Risk Identification and Analysis (ARIA) System | Publications and Presentations | 05/25/2023 | An Assessment of the Sentinel System: Focus on the Active Risk Identification and Analysis (ARIA) SystemPublications and Presentations 05/25/2023 |
https://www.sentinelinitiative.org/studies/drugs/new-molecular-entities-nmes | New Molecular Entities (NMEs) & Utilization Characterization | Studies | 05/30/2023 | New Molecular Entities (NMEs) & Utilization CharacterizationStudies 05/30/2023 |
https://www.sentinelinitiative.org/methods-data-tools/methods/data-expansion-implementation-linking-national-death-index-ndi-data | Data Expansion Implementation: Linking the National Death Index (NDI) data to the Sentinel Distributed Database (SDD) | Methods, Data, & Tools | 06/01/2023 | Data Expansion Implementation: Linking the National Death Index (NDI) data to the Sentinel Distributed Database (SDD)Methods, Data, & Tools 06/01/2023 |
https://www.sentinelinitiative.org/studies/drugs/zarxio-filgrastim-sndz | Zarxio (Filgrastim-sndz) & Signal Identification | Studies | 06/01/2023 | Zarxio (Filgrastim-sndz) & Signal IdentificationStudies 06/01/2023 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/mortality-following-long-acting-injectable-antipsychotics | Mortality Following Long-Acting Injectable Antipsychotics Use in Patients with Dementia: An Inverse Probability of Treatment Weighting Analysis | Analyses | 06/08/2023 | Mortality Following Long-Acting Injectable Antipsychotics Use in Patients with Dementia: An Inverse Probability of Treatment Weighting AnalysisAnalyses 06/08/2023 |
https://www.sentinelinitiative.org/studies/drugs/long-acting-injectable-antipsychotics | Long-Acting Injectable Antipsychotics & Mortality | Studies | 06/08/2023 | Long-Acting Injectable Antipsychotics & MortalityStudies 06/08/2023 |
https://www.sentinelinitiative.org/news-events/meetings-workshops-trainings/multi-wave-validation-sampling-improve-estimates-derived | Multi-wave Validation Sampling to Improve Estimates Derived from Electronic Health Record Data | Sentinel Initiative Events | Multi-wave Validation Sampling to Improve Estimates Derived from Electronic Health Record DataSentinel Initiative Events 07/11/2023 |
|
https://www.sentinelinitiative.org/news-events/meetings-workshops-trainings/leveraging-missing-data-and-measurement-error-approaches-0 | Leveraging Missing Data and Measurement Error Approaches in Propensity Score-Based Analyses of Real-World Data | Sentinel Initiative Events | Leveraging Missing Data and Measurement Error Approaches in Propensity Score-Based Analyses of Real-World DataSentinel Initiative Events 08/21/2023 |